Novartis’ Canakinumab Fails to Meet its Primary Endpoint in P-III CANOPY-2 Study

March 10, 2021 Auto Bot Clinical Trials, Non-Small Cell Lung Cancer, Novartis, P-III study, reports, results, Treatment, VIR-7831 0

Shots:

  • The P-III CANOPY-2 study involves assessing canakinumab (ACZ885) + CT (docetaxel) in 237 adults with LA/m-NSCLC, prior treatment with PD-L1 inhibitors and Pt-based CT. The study did not meet its 1EPs of OS
  • The company will continue to evaluate the therapy in ongoing P-III CANOPY-1 and CANOPY-A studies evaluating canakinumab in 1L and adjuvant settings. The CANOPY-1 results are expected before the end of 2021
  • Canakinumab is a mAb that binds with high affinity and selectivity to human IL-1β and acts by blocking its interaction with its receptor

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: La Libre

The post Novartis’ Canakinumab Fails to Meet its Primary Endpoint in P-III CANOPY-2 Study first appeared on PharmaShots.